Benzinga
Benzinga
Benzinga
domenica, settembre 27

Travere Therapeutics Inc

TVTXNASDAQ
Trade with Public
Trade with Public
$59.44
-1.18-1.95%
In chiusura: Sep 25, 5:00 PM EST
$59.00
-0.44-0.74%
Post-mercato: Sep 25, 6:03 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Travere Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Travere Therapeutics (TVTX).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

13Buy
2Hold
Consensus RatingBuy# Analysts15Avg. Consensus PT$50Upside to Avg. PT-14.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Sep 24, 2026GuggenheimVamil DivanPT RaiseBuy$75→$89
Sep 22, 2026WedbushLaura ChicoMaintainedOutperform$76
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $75 to $89.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $76 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $67 price target.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $68 to $78.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $61 to $75.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved